Aeterna Zentaris’ AEZS-130 demonstrates potential as oral diagnostic check for AGHD Aeterna Zentaris Inc. The info was presented previous today by Beverly M.K facts about drugs . Biller, M.D. Of the Harvard Medical School/Massachusetts General Medical center in Boston, at the 5th International Congress of the GROWTH HORMONES Research Culture and the Insulin-like Growth Factors Society in New York City. AEZS-130 provides been granted Orphan Drug Designation by the meals and Medication Administration as a diagnostic test for AGHD.
It hopes to possess at least 100,000 employees enrolled by early following year .This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news services, is a scheduled plan of the Kaiser Family members Foundation, a nonpartisan health care policy research firm unaffiliated with Kaiser Permanente.. Aetna becomes California’s third insurer to scale back rate hikes Meanwhile, a fresh insurance market trend is picking right up steam as one of the nation’s largest employer-benefits consulting companies announced that it will launch a private exchange for large businesses.